Company Overview

Investor Presentation

August 2019

Exhibit 99.1

2

The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.

The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety by reference to reports

filed with the SEC. Certain information in this presentation has been obtained from outside sources or is anecdotal in nature. While such information

is believed to be reliable for the purposes used herein, no representations are made as to the accuracy or completeness thereof and we take no

responsibility for such information.

Any

discussion

of

the

potential

use

or

expected

success

of

Rhopressa

®

(netarsudil

ophthalmic

solution)

0.02%

or

Rocklatan

®

(netarsudil

and

latanoprost

ophthalmic

solution)

0.02%/0.005%,

with

respect

to

foreign

approval

or

additional

indications,

and

our

current

or

any

future

product

candidates,

including

AR-1105

and

AR-13503,

is

subject

to

regulatory

approval.

In

addition,

any

discussion

of

U.S.

Food

and

Drug

Administration

(“FDA”)

approval

of

Rhopressa

®

or

Rocklatan

®

does

not

guarantee

successful

commercialization

of

Rhopressa

®

or

Rocklatan

®

.

For

more

information

on

Rhopressa

®

,

including

prescribing

information,

refer

to

the

full

Rhopressa

®

product

label

at

www.rhopressa.com.

For

more

information

on

Rocklatan

®

,

including

prescribing

information,

refer

to

the

full

Rocklatan

®

product

label

at

www.rocklatan.com.

The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to

update this information in light of new information, future events or otherwise. We are not making any representation or warranty that the information

in this presentation is accurate or complete.

Certain statements in this presentation, including any guidance or timelines presented herein, are “forward-looking statements” within the meaning

of

the

federal

securities

laws.

Words

such

as

“may,”

“will,”

“should,”

“would,”

“could,”

“believe,”

“expects,”

“anticipates,”

“plans,”

“intends,”

“estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking statements. These statements are

based on the Company’s current plans and expectations. Known and unknown risks, uncertainties and other factors could cause actual results to

differ

materially

from

those

contemplated

by

the

statements.

In

evaluating

these

statements,

you

should

specifically

consider

various

factors

that

may cause our actual results to differ materially from any forward-looking statements. In particular, these statements include any discussion of

potential commercial sales, placement or utilization of Rocklatan or Rhopressa in the United States or any other market. Likewise,  FDA approval of

Rhopressa

®

and

Rocklatan

®

does

not

constitute

approval

of

any

future

product

candidates.

Any

top

line

data

presented

herein

is

preliminary

and

based

solely

on

information

available

to

us

as

of

the

date

of

this

presentation

and

additional

information

about

the

results

may

be

disclosed

at

any

time.

FDA

approval

of

Rhopressa

®

and

Rocklatan

®

also

does

not

constitute

regulatory

approval

of

Rhopressa

®

or

Rocklatan

®

in

jurisdictions

outside

the

United

States

and

there

can

be

no

assurance

that

we

will

receive

regulatory

approval

for

Rhopressa

®

or

Rocklatan

®

in

jurisdictions

outside

the

United States. In addition, the development work being undertaken for our pipeline and the preclinical research discussed in this presentation

including, without limitation, the development efforts stemming from Aerie’s collaboration with DSM for the treatment of age-related macular

degeneration or other ophthalmic uses, is preliminary and the outcome of such preclinical studies may not be predictive of the outcome of later

trials. Any future clinical trial results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the preclinical

research

findings

discussed

in

this

presentation.

These

risks

and

uncertainties

are

described

more

fully

in

the

quarterly

and

annual

reports

that

we

file with the SEC, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of

Operations.” Such forward-looking statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any

forward-looking statements, whether because of new information, future events or otherwise, except as otherwise required by law.

For Investor Use

Important Information

3

For Investor Use

Aerie Overview

Rhopressa

®

and

Rocklatan

®

have

not

been

approved

by

any

regulatory

authority

other

than

the

FDA.

Additional

potential

Rhopressa

®

indications

are

being

considered for further study and are not labeled indications. AR-13503 and AR-1105 are pre-clinical molecules and have not been approved by FDA.

Aerie IOP–Reducing Products (IP 2030+)

Pipeline Activities

•

Rhopressa

®

–

normal

tension

glaucoma,

pseudo

ex

glaucoma,

corneal

healing...

•

Retina

Program

–

AR-13503

(IND

accepted

by

FDA

Q2

2019)

and

AR-1105

(Phase 2 clinical study commenced Q1 2019) implants

•

Sustained-Release Implant Manufacturing Platform

•

Beyond

Ophthalmology

–

potential

for

Aerie-owned

molecules

•

Rhopressa

®

(netarsudil ophthalmic solution) 0.02%

•

Successful U.S. Launch in 2018

•

Rocklatan

®

(netarsudil

and

latanoprost

ophthalmic

solution)

0.02%/0.005%

•

Launched May 1, 2019

•

Second drug product contract manufacturer approved  for

Rhopressa

®

; 

Aerie Ireland plant expected to be online early 2020

•

Globalization

Plan

Under

Way

–

Europe

and

Japan

4

For Investor Use

Glaucoma Market Perspective

-

~$3B Market, 35M TRx, 52M bottles

-

Half of volume first-line (PGAs)

-

Half of volume 2-3X/Day Adjuncts

2018 U.S. Glaucoma Market

Graph Source: IQVIA 2018

CAI: Carbonic Anhydrase Inhibitor

AA: Alpha Agonist

BB: Beta Blocker

Source: IMS/NPA Data R12M May’18-Apr’19 and Aerie company estimates.

Estimated

Glaucoma

Market

TRx

Mix

Lumigan

6%

Travatan

5%

Latanoprost

41%

Other

BB

14%

Fixed

Combo

13%

AA

10%

CAI

7%

Medicare Part D

Commercial

Other Government

Medicaid & Cash

Other Government 8%

Medicaid & Cash 7%

Medicare Part D

51%

Commercial

34%

5

For Investor Use

Rhopressa

®

and Rocklatan

®

Positioning

HCP’s positioning as

concomitant therapy

HCP’s positioning as therapy

for patients requiring maximal

IOP lowering with one drop per

day

Rhopressa

®

Positioning

Rocklatan

®

Positioning 

•

Efficacy vs. other adjunctive therapies

•

QD PM dose

•

Lack of serious and systemic AE’s

•

Efficacy vs. all other glaucoma therapies

•

QD PM dose

•

Lack of serious and systemic AE’s

Refer to the full product labels at www.rhopressa.com and www.rocklatan.com

6

For Investor Use

Rocklatan

®

Phase 3 Month 12 Responder Analysis:

Goal is to Achieve Lowest IOP Possible

At Month 12:  % of Patients

with IOP Reduced to 18 mmHg or Lower

16%

26%

37%

49%49%

57%

12%

22%

35%

66%

27%

43%

60%

72%

82%

0%

20%

40%

60%

80%

100%

   14 mmHg

   15 mmHg

   16 mmHg

   17 mmHg

   18 mmHg

IOP on Treatment

Rhopressa  (n=148)

Latanoprost (n=203)

Rocklatan

***

**

®

®

*p<0.05, **p<0.01, ***p<0.0001

++

Data on File

Based on Mercury 1 Interim Analysis 2

Rocklatan

®

has not been approved by any regulatory authority other than the FDA.

*

**

***

7

For Investor Use

U.S. Glaucoma Franchise Launch Update

Actual Sales-Out to Pharmacies data and

IQVIA data as of 8/2/19

Actual bottles dispensed exceed Rx’s due to extended supply plans (e.g., 90 days’ supply)

Rhopressa

®

and Rocklatan

®

have not been approved by any regulatory authority other than the FDA.

7,362

8,630

9,598

11,294

11,858

14,199

4/13/2018

12/31/2018

8/2/2019

0

3,000

6,000

9,000

12,000

15,000

Franchise Actual Sales-Out to Pharmacies

Rhopressa® Actual Sales-Out to Pharmacies

Franchise IQVIA Bottles

Rhopressa® IQVIA Bottles

Franchise IQVIA Rx

Rhopressa® IQVIA Rx

8

For Investor Use

Gaining Market Access

Access percentages reflect signed contracts, not necessarily implemented underlying formulary coverage.

•

Rhopressa

®

Access as of August 2019:

–

Commercial ~ 90%

–

Medicare Part D ~ 75%

•

Rocklatan

®

Expected Access by end of September 2019:

–

Medicare Part D ~ 30%  (Rhopressa

®

~10% in September 2018)

9

For Investor Use

2019 Financial Guidance

•

Net revenue guidance: $70 to $80 million

•

Net cash burn guidance: $160 to $170 million

10

For Investor Use

Launch Considerations

•

Aerie is in the unique position of gaining coverage for Rocklatan

®

while

continuing to grow Rhopressa

®

–

Underlying formulary coverage is sometimes delayed

•

Physicians are navigating through the treatment paradigm to optimize patient

care while considering patient costs

•

Rocklatan

®

samples are being used with excellent results, but without

coverage physicians may add Rhopressa

®

on top of a PGA as an affordable

interim solution

–

Busy practices may not have patients return for 60 days

•

Dosing, simplicity and efficacy of Rocklatan

®

is widely recognized and there

appears to be a high willingness for physicians to use it as a first-line agent

Patient access and affordability are key to continued market share gains

11

For Investor Use

Active Engagement at Key Conferences

•

March 2019: American Glaucoma Society (AGS)

•

April/May 2019: Association of Research in

Vision and Ophthalmology (ARVO)

•

May 2019: American Society of Cataract and

Refractive Surgeons (ASCRS)

•

July 2019: American Society for Retina

Specialists (ASRS)

•

September 2019: European Society of Cataract

and Refractive Surgeons (ESCRS)

•

September 2019: Japan Glaucoma Society

(JGS)

•

October 2019: American Academy of

Ophthalmology (AAO)

12

For Investor Use

Expanding Aerie Franchise: Europe

•

MAA

accepted

for

Rhokiinsa

®

(Rhopressa

®

)

in

October

2018,

regulatory

decision

expected

by end of 2019

•

Mercury

3:

6-month

safety

and

90-day

efficacy

registration

trial

comparing

Rocklatan

®

(known

as

Roclanda

®

in

Europe)

for

non-inferiority

to

a

fixed-dose

combo

in

Europe

(Ganfort

®

)

•

If

Rhokiinsa

®

is

approved,

plan

to

submit

Roclanda

®

MAA

thereafter

(Q1

2020)

•

Ireland Plant will begin supporting worldwide commercial supply in early 2020

•

Mercury 3 top-line readout expected in 1H 2020

•

Aerie expects to commercialize on its own (if approved)

Sources:

IMS

Analytics

Link

at

ex-manufacturer

price

level-

March

2019.

*TRx

calculated

from

IQVIA

unit

data

(1

month

=

1

TRx)

13

For Investor Use

Expanding Aerie Franchise: Japan

•

Advancing clinical development on our own, established branch office in Tokyo

•

Phase 1 completed; successful Pilot Phase 2 completed in the U.S. on Japanese and

Japanese-Americans; Phase 2 commenced in Japan, enrollment completed July 2019

•

Phase 2 Study top-line readout expected in Q4 2019

•

Phase 3 trials expected to be conducted in Japan

•

Aerie evaluating commercialization alternatives including partnering

Sources:

IQVIA

Analytics

Link

at

ex-manufacturer

price

level

–

March

2019.

*TRx

calculated

from

IQVIA

unit

data

(1

month

=

1

TRx)

Advancing the Pipeline

Drug/Target

Indication

Development Stage

Discovery

Preclinical

Phase 1/2a

AR-1105 Implant

(Dexamethasone)

RVO

AR-13503 Implant

(ROCK, PKC)

wAMD

DME/DR

Glaucoma Neuro-

enhancement

AR-xxxxx

Implant

(ROCK/JAK/IKK)

Dry AMD/GA

AR-xxxxx

(JAK, IKKb)

Dry Eye/MGD

AR-xxxxx

(ROCK, JAK, IKKb)

Psoriasis

IND

IND

Evaluating Aerie’s 4,000+ Owned Molecules

For Investor Use

14

15

For Investor Use

Retinal Eye Diseases –

Aerie’s Next Chapter

Bringing Small Molecule Therapy to Back of the Eye

•

Most retinal drugs in use and in pipeline are protein therapeutics

•

Longer half-life allows monthly to bimonthly IVT injections

•

Protein therapeutics address limited number of extracellular targets

•

Small molecules address a wider array of therapeutic targets, but are

rapidly cleared from back of the eye

The Solution:

Pair small molecules with a safe and effective sustained delivery

technology

to

enable

IVT

injections

every

4

-

6

months

16

For Investor Use

2018 U.S. Retinal Disease Market

Eylea,

$4.1

Avastin,

$0.04

Lucentis,

$1.7

steroids,

$0.2

others,

$0.02

2018 Sales: $6.0B

2018 Unit Sales: 7.3MM

Eylea, 2.1

Avastin,

3.9

Lucentis,

1.0

steroids,

0.2

others,

0.1

Sources:

Mixture

of

public

information,

IQVIA,

Market-Scope

and

estimates

–

March

2019        

17

For Investor Use

Aerie’s Innovation in Retinal Disease

Small Molecule Drug

Candidates

Proprietary Drug Delivery

Technology

•

Bio-erodible,

sustained-release

implant for

intravitreal injection

•

DSM PEA Polymer

•

PLGA

•

PRINT® Mfg

AMD       DME      RVO      Dry AMD/GA      Glaucoma       Others

•

Aerie Kinase Library

•

Non-Aerie drug candidates

18

For Investor Use

Retinal Eye Disease: Unmet Needs in AMD and DME

•

Need new treatments to address disease mechanisms beyond VEGF

•

Complex pathology cannot be addressed by a single drug class

•

Anti-VEGFs are used to treat the eye with wet AMD, while the

second eye typically has dry AMD and a high risk of converting to

wet AMD over time. There are no current treatment approaches

to prevent this conversion.

•

Many patients do not achieve and/or maintain sufficient efficacy

•

AMD: Anti-VEGF efficacy often lost after 5–7 years of treatment

•

DME: Anti-VEGF is ineffective for ~1/3 of DME patients

Need treatments that are effective with less frequent intravitreal injections

19

For Investor Use

Aerie’s Lead Retina Product Candidates

AR-1105 (Dexamethasone) Implant

•

Indications: retinal vein occlusion (RVO) and DME

•

Target product profile vs. Ozurdex

®

•

Longer duration of efficacy (6 mo

vs 3 mo)

•

Improved administration due to smaller needle

•

Potential for fewer adverse effects due to lower peak drug levels

AR-13503 (ROCK/PKC) Implant

•

Initial indications: neovascular AMD and DME

•

Novel MOA: anti-angiogenesis PLUS anti-fibrosis, anti-inflammation

•

Effective as monotherapy or adjunctive therapy to anti-VEGF

•

Targeting injection once every 6 months

For

more

information

on

Ozurdex®

please

see

the

product

webpage

https://www.ozurdex.com

AR-1105 and AR-13503 are development stage product candidates and are not approved by any regulatory agency

20

For Investor Use

AR-13503

Synergistic

to

Eylea

®

in

Mouse

Model

of

Proliferative Diabetic Retinopathy

Oxygen-induced retinopathy (OIR) mouse model -

PDR

0%

5%

10%

15%

20%

25%

30%

35%

Vehicle

n=12

Eylea (sub-

optimal dose)

n=12

AR-13503 (sub-

optimal dose)

n=14

Combination

n=8

-40%

*

Administration: Intraperitoneal QD

* :    p<0.01

*** : p<0.0001

-60%

Neovascular Area (+SEM)

Data on File

Sub-optimal dose levels selected in the study to provide less than maximal efficacy

For

more

information

on

Eylea®

please

see

the

product

webpage

https://www.eylea.us/

AR-13503 is a development stage product candidate and is not approved by any regulatory agency

***

21

For Investor Use

Summary

•

Key Priorities

•

Rhopressa

®

:  Continued successful launch execution

•

Rocklatan

®

:  Successful launch execution

•

Globalization Strategy

•

Europe/Japan clinical path and commercialization strategy

•

Ireland Manufacturing Facility

•

Research Initiatives

•

Rhopressa

®

normal tension glaucoma, pseudoexfoliative

glaucoma, corneal healing    

•

Retina Program:

-

AR-1105 Phase 2 clinical study commenced in Q1 2019; AR-13503 IND accepted Q2 2019,

to enter clinic in Q3 2019

•

Broad sustained release ophthalmic implant and manufacturing platform

•

Evaluating Aerie’s ROCK inhibitors beyond ophthalmology

•

Well-Financed

•

$109M cash/investments at 6/30/19; $200M undrawn credit facility